ModernGraham Valuation

Company Name:

Company Ticker

Date of Analysis

Hologic, Inc.

6/10/2018



Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

HOLX

1. Adequate Size of the Enterprise	Market Cap > \$2Bil	\$10,467,240,056 Pass
2. Sufficiently Strong Financial Condition	Current Ratio > 2	1.26 Fail
3. Earnings Stability	Positive EPS for 10 years prior	Fail
4. Dividend Record	Dividend Payments for 10 years prior	Fail
	Increase of 33% in EPS in past 10 years using 3 year averages at	
5. Earnings Growth	beginning and end	-147.29% Fail
Moderate PEmg Ratio	PEmg < 20	36.87 Fail
7. Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	4.34 Fail

Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.

1. Sufficiently Strong Financial Condition	Current Ratio > 1.5	1.26 Fail
2. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	8.16 Fail
3. Earnings Stability	Positive EPS for 5 years prior	Pass
Dividend Record	Currently Pays Dividend	Fail
5. Earnings Growth	EPSmg greater than 5 years ago	Pass

95 75%

Score

Suitability

MG Opinion

Defensive No Enterprising No

Stage 2: Determination of Intrinsic Value

EPSmg	\$1.04
MG Growth Estimate	15.00%
MG Value	\$40.04
MG Value based on 3% Growth	\$15.08
MG Value based on 0% Growth	\$8.84
Market Implied Growth Rate	14.18%
Current Price	\$38.34

% of Intrinsic Value Opinion **Fairly Valued**

MG Grade


Stage 3: Information for Further Research

Net Current Asset Value (NCAV)	-\$11.38
Graham Number	\$5.23
PEmg	36.87
Current Ratio	1.26
PB Ratio	4.34
Current Dividend	\$0.00
Dividend Yield	0.00%
Number of Consecutive Years of Dividend	
Growth	0

Useful Links: ModernGraham tagged articles

Morningstar Google Finance MSN Money Yahoo Finance Seeking Alpha <u>GuruFocus</u> **SEC Filings**

EPS History		EPSmg History	
Next Fiscal Year			
Estimate	• •	Next Fiscal Year Estimate	\$1.04
Sep2017	\$2.64	Sep2017	\$1.00
Sep2016	\$1.16	Sep2016	-\$0.08
Sep2015	\$0.45	Sep2015	-\$0.70
Sep2014	\$0.06	Sep2014	-\$1.14
Sep2013	-\$4.36	Sep2013	-\$2.02
Sep2012	-\$0.28	Sep2012	-\$1.24
Sep2011	\$0.59	Sep2011	-\$1.75
Sep2010	-\$0.24	Sep2010	-\$2.56
Sep2009	-\$8.64	Sep2009	-\$3.07
Sep2008	-\$1.57	Sep2008	-\$0.19
Sep2007	\$0.86	Sep2007	\$0.45
Sep2006	\$0.28	Sep2006	\$0.21
Sep2005	\$0.32	Sep2005	\$0.13
Sep2004	\$0.15	Sep2004	-\$0.01
Sep2003	\$0.04	Sep2003	-\$0.10
Sep2002	\$0.00	Sep2002	-\$0.15
Sep2001	-\$0.34	Balance Sheet Information	3/1/2018
Sep2000	-\$0.31	Total Current Assets	\$1,635,200,000
Sep1999	-\$0.07	Total Current Liabilities	\$1,299,600,000
Sep1998	\$0.19	Long-Term Debt	\$2,739,200,000
	<u> </u>	Total Assets	\$7,234,400,000
		Intangible Assets	\$5,041,900,000
		Total Liabilities	\$4,788,800,000
		Shares Outstanding (Diluted Average)	277,114,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other ModernGraham posts about the company Hologic Inc Valuation – Initial Coverage \$HOLX

Other ModernGraham posts about related companies Mettler-Toledo International Inc Valuation – June 2018 \$MTD
Envision Healthcare Corp Valuation – June 2018 \$EVHC
DaVita Inc Valuation – June 2018 \$DVA
Danaher Corp Valuation – May 2018 \$DHR
Agilent Technologies Inc Valuation – May 2018 \$A
Cooper Companies Inc Valuation – May 2018 \$COO
Edwards Lifesciences Corp Valuation – May 2018 \$EW
Baxter International Inc Valuation – May 2018 \$BAX
Boston Scientific Corp Valuation – May 2018 \$BSX

Centene Corp Valuation - May 2018 \$CNC